Table 2.

Effects of ranitidine treatment on plasma soluble mediator levels.

	LOD	# above LOD at baseline	T0	T3	T6	T18	ANOVA P-value
BAFF	1.43	29	126.7 ± 8.03	117.6 ± 7.47	136.9 ± 11.79	110.5 ± 7.24	0.0562
CCL2	1.69	29	25.15 ± 1.84	23.84 ± 1.82	24.12 ± 2.08	21.12 ± 1.74	0.1582
CCL5	0.19	29	55.9 ± 1.25	53.77 ± 1.90	58.9 ± 1.73	54.07 ± 1.90	0.0109
CXCL1	1.28	0	N.D	N.D	N.D	N.D	–
G-CSF	3.96	2	1.17 ± 0.48	1.09 ± 0.37	3.61 ± 1.03	6.35 ± 1.02**	< 0.0001
IFNγ	6.51	1	7.37 ± 0.86	7.02 ± 0.51	6.51 ± 0.00	6.89 ± 0.38	0.3916
IL-1β	0.86	12	5.47 ± 1.53	3.27 ± 1.09	1.81 ± 0.63	2.05 ± 0.57	0.0239
IL-1R	71.53	0	N.D	N.D	N.D	N.D	–
IL-2	2.45	25	15.24 ± 1.75	8.14 ± 1.46 ****	5.78 ± 0.91****	5.07 ± 1.04*	< 0.0001
IL-6	4.53	1	6.71 ± 2.18	6.002 ± 1.47	5.51 ± 0.89	5.58 ± 1.05	0.3916
IL-7	0.38	28	2.05 ± 0.19	1.68 ± 0.20	1.97 ± 0.18	2.70 ± 0.23	0.0005
IL-8	1.19	0	N.D	N.D	N.D	N.D	–
IL-10	0.73	9	1.04 ± 0.09	0.79 ± 0.04	0.73 ± 0.00	0.73 ± 0.00	< 0.0001
IL-15	1.31	14	8.03 ± 1.90	6.63 ± 1.73	4.98 ± 1.56	4.81 ± 1.60	0.1644
M-CSF	7.14	0	N.D	N.D	N.D	N.D	–
MMP9	0.39	29	58.06 ± 4.21	50.39 ± 4.66	60.35 ± 7.86	54.25 ± 6.78	0.0664
TNF	3.72	4	5.62 ± 1.31	4.61 ± 0.89	3.72 ± 0.56	4.48 ± 0.76	0.0134
VEGF-A	2.34	29	29.33 ± 2.91	31.84 ± 4.24	34.54 ± 5.56	32.01 ± 5.02	0.4599

Plasma soluble mediators were measured before treatment (T0) after 3-and 6-weeks treatment (T3 and T6) and after 12 weeks treatment cessation (T18) by multiplex immunoassay or ELISA. The values depicted represent concentrations (pg/ml) ± SEM. Statistical analysis was performed using a Friedman’s test followed by Dunn’s multiple comparison, or, where appropriate for data distribution, repeated measures one-way ANOVA test followed by Dunnett’s multiple comparison, using T0 as control. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to T0. ND, not detectable (analyte below the LOD in > 85% of individuals, across timepoints).

LOD limit of detection.